Indaptus Therapeutics is trading 5.07% up now at $3.73 after its September 18, 2026, close at $3.55, down 9.67%; no fresh company-specific announcement explaining the after-hours rise was identified.
- Latest catalyst: the September 8 private placement announced in September, stale rather than a same-day trigger, targeting approximately $24 million for working capital, research and development, and potential neurotechnology work.
- Markets were mixed; the Nasdaq Composite rose 0.80%, which may have supported the rebound, though the specific cause remains unclear.